



PRESS RELEASE

Company Contact:

Elizabeth Hutt
Vice President, Sales and Technical Service
650-590-3600
ehutt@nugeninc.com

Media Contact:

Carolyn Hawley
Atkins + Associates for NuGEN Technologies
858-527-3484
chawley@irpr.com

NuGEN Announces the Adoption of the Ovation™ Biotin System by Top-Ranked Institution

Facility to use Ovation Biotin System for Affymetrix GeneChip® arrays

San Carlos, California — October 5, 2004 — NuGEN Technologies, Inc., a privately held company developing and commercializing the new standard in nucleic acid amplification and labeling systems, announced the adoption of the Ovation™ Biotin System for use with Affymetrix GeneChip® arrays at the Microarray Core Facility at Weill Cornell Medical College in New York City.

NuGEN offers three Ovation Systems for amplifying and labeling RNA for gene expression analysis. The Ovation Biotin System is validated for use with Affymetrix GeneChip arrays, the Ovation Aminoallyl System is used with spotted oligo or cDNA arrays, and the Ovation RNA Amplification System is designed to amplify RNA prior to quantitative real-time PCR (QPCR). The Systems are powered by NuGEN's proprietary Ribo-SPIA™ technology, which enables rapid, simple, and sensitive RNA amplification for gene expression analysis.

"The Ovation Biotin System allowed us to generate results for one of our researchers on samples that had never succeeded before in microarray analysis," said Jenny Xiang, M.D., Director of the Weill Cornell Medical College Microarray Core Facility. "The exceptional quality of cDNA that we generated gave us excellent microarray results, and with the rapid protocol, we saved time compared to our traditional amplification method. We plan to recommend the Ovation System to all of the Microarray Core Facility users who are performing GeneChip analysis on small samples."

Weill Medical College of Cornell University is among the top-ranked clinical and medical research centers in the country. The institution is affiliated with NewYork-Presbyterian Hospital, Memorial Sloan-Kettering Cancer Center, Hospital for Special Surgery, and the metropolitan-area institutions that constitute the NewYork-Presbyterian Healthcare System. The Microarray Core Facility at Weill Cornell Medical College helps biomedical researchers explore questions systematically by providing high throughput technology with flexibility and simplicity for efficient extraction of biologically meaningful data.

About NuGEN Technologies Inc.

NuGEN Technologies is focused on the development and commercialization of sensitive, rapid and cost-effective amplification and detection systems for genomic and proteomic research. The company's technologies enable the comprehensive analysis and discovery of biological mechanisms, cellular responses, and disease pathologies. NuGEN's proprietary SPIA™ and Ribo-SPIA™ amplification and labeling technology for DNA and RNA based applications, form the foundation for a wide range of methods and products used by life scientists. The Ovation™ amplification and labeling system, the company's first commercially available product line, has applied these technologies to enhancing the sensitivity, convenience, and accuracy of gene expression analysis. Based in San Carlos, CA, NuGEN has a world-class investor syndicate, several collaborations with leading academic and commercial organizations and a management team with significant experience developing and marketing products for research or clinical diagnostic applications.

NuGEN, Ovation, SPIA and Ribo-SPIA are trademarks or service marks of NuGEN Technologies, Inc.

This press release contains forward-looking statements that are subject to risks and uncertainties, including continued growth in demand by researchers for total RNA analysis, continued use of oligo and cDNA microarrays, acceptance by researchers of the Company's technologies and products, and competition from existing and newly developed products. Accordingly, actual results may differ materially from those anticipated. These forward-looking statements represent the Company's current expectations as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

###